Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Venus Pipes IPO Review and Brokerage Calls – May Apply

By Jagat Joshi
May 7, 2022

Venus Pipes & Tubes Limited IPO is to open on May 11 for the subscription. The company is going to raise ₹165.42 crores from the primary market via initial public offerings. They fixed the price band at ₹310 to ₹326 per equity share. The IPO will remain open till May 13.

Venus Pipes & Tubes Limited is a manufacturer of stainless steel pipes and tubes. As per the current scenario, the commodity prices rising in the sector might give benefit the company with higher margins in its business. The company is aiming to expand its business. The company reported ₹312 crores revenues in 2021 against ₹179 crores in 2022. Based on the earnings it impacted very high on the profit that shown a rise on 6 times in 2021 to ₹23.63 crores against ₹4.13 crores in 2020. The financial results show that 2022 will be a good year as the 3 months data shows good improvement as well.

About Company:

Gujarat Based Venus Pipes Limited is a manufacturer and exporter of stainless steel tubular products like stainless steel pipes and tubes. The company’s manufacturing plant is located in Kutch, Gujarat, The production facility is spread across 11 acres area. They have an installed capacity of 10,800 MT per annum. The company has a global presence in more than 18 countries internationally.

Venus Pipes product range includes Stainless Steel High Precision and Heat Exchanger Tubes, Stainless Steel Hydraulic and Instrumentation Tubes, Stainless Steel Seamless Pipes, Stainless Steel Welded Pipes, and Stainless Steel Box Pipes. They sell their products in local markets of India and countries including Brazil, the UK, Israel, and European Union, etc.

Listed Peers Comparision:

Jindal Saw Limited and Ratnamani Metal & Tubes Limited are the listed peer group companies. The P/E is trading at 32.96 and 6.21 as of May 06, 2022. Jindal Saw is trading in the range between ₹90 to ₹110 last year while Ratnamani Metal & Tubes is trading in the range between ₹1900 to ₹2600 in last one year.

Antique Stock Broking IPO Review:

Doubling capacity in the niche stainless steel pipe segment Venus Pipes & Tubes Limited (Venus) is a Gujarat-based manufacturer & exporter of stainless-steel pipes & tubes, primarily catering to industry-grade requirements with end uses spanning across chemicals, pharmaceuticals, food processing industries and other engineering needs. Global stainless steel (SS) pipes & tubes industry was estimated to be valued at USD32.4 bn in 2019 and is expected to grow at a CAGR of 4% through 2025. India’s per capital stainless steel consumption at 2.5 kg in 2019 is significantly lower compared to the world average of 6 kg per capita indicating the opportunities existing in the sector. Indian per capita consumption of steel pipes and tubes is less than half of the global average (21-22 kg) and about one-fifth of the Chinese consumption.

The company’s FY21 revenue jumped 74% YoY to INR3,093mn aided by increased volume, higher capacity utilization driven by a robust growth of domestic and export demand. Venus increased its capacity from 6.9ktpa to 10.8ktpa over FY19-21. Increasing capacity utilization has driven a 60% revenue CAGR over the period. The net debt amounts to INR631mn (as on 31.12.2021, including LC of INR 205.1mn) and leverage level at ~0.4x debt/ equity is comfortable. Return ratios have improved strongly with strong asset utilization & improved profitability. Venus Pipes is planning to double capacity to meet the rising demand, enrich the product portfolio, enhance operational efficiency through backward integration and aims to raise the required funding through the IPO route.

Strong capacity expansion plans to drive revenues

Currently, the company has a total production capacity of 10.8 ktpa, of which 3.6 ktpa is dedicated to seamless SS pipes & 7.2 ktpa for welded SS pipes. The company plans to expand its seamless capacity to 9.6 ktpa and welded capacity to 14.4 ktpa, in addition to 9.6 ktpa of new capacity towards backward integration to manufacture mother hollow pipes.

Total capacity would double from 10.8ktpa to 24ktpa.

Backward integration and enriched product mix to improve margins Backward integration with in-house production of hollow pipes, acquisition of slitting machine for cutting steel strips/coils as per desired width and enriched product mix with higher diameter pipes would lead to continued improvement in margins.

Export and domestic opportunities to increase with removal of Chinese export rebate

China accounted for 54% of India’s total SS pipes & tubes imports in FY21. The cancellation of export rebates on Chinese steel products including welded and seamless steel pipes, as announced by the Chinese Government on 28 April 2021, is expected to erode away the cost advantage enjoyed by Chinese manufacturers, providing impetus to domestic pipes and tubes manufacturers. Domestic manufacturers are also protected with the stipulation that only BIS-certified products can be used for projects in the country.

Capex in chemical and pharmaceuticals industry to drive demand

SS Pipes & tubes are used across the chemical, engineering, pharmaceuticals and food processing Industries, among others. Venus Pipes & Tubes Ltd derives around 33% of its sales from chemicals (19%) and engineering (14%) segment. Approximately 10% of the capital expenditure for a chemical plant is in the form of SS pipes & tubes. The Atmanirbhar Bharat Initiative and other PLI schemes are set to boost these sectors, thus driving the demand for SS pipes & tubes in the country.

Centrum Institutional Research IPO Review:

Impressive growth in short term; operating performance to improve further

During FY19-21, it has grown well with sales CAGR of 61% to Rs3.09bn and EBITDA CAGR of 105% to Rs348mn in FY21. During 9MFY22, it has already surpassed FY21 numbers and recorded EBITDA of Rs355mn. The EBITDA margins improved from ~7% in FY19 to ~12.8% in 9MFY22. Blended EBITDA/t inched up sharply from ~Rs19,813/t in FY19 to ~Rs38,906/t in Q1FY22. As a result, PAT increased by ~94% CAGR to Rs272mn. Significant higher earnings improved return ratios. ROE improved sharply from 31% in FY19 to 59% in FY21 while ROCE improved from 14.7% in FY19 to 36% in FY21.

Doubling SS pipes capacity by FY23 end, backward integrating helps in securing growth

Venus has a manufacturing plant having installed capacity of 10,800tpa of SS pipes and tubes at Kutch, Gujarat. It has high diameter welded pipes of 7,200tpa (66%) and high diameter seamless pipes of 3,600tpa (33%). The capacity utilization has improved from average 61% in FY19 to 92% in FY21. Venus has embarked to expand capacity to 24,000tpa, expected to be commissioned by FY23 end. Post commissioning, welded pipes will be 14,400tpa (60%) and seamless pipes 9,600tpa (40%). The capital outlay required for expansion project is ~Rs1060mn funded through IPO proceeds. Future growth will be fueled from both volume expansion as well as cost saving on account of backward integration as it is setting up 9,600tpa piercing plant for seamless pipes which can help in saving Rs15-20k/t (at full capacity utilization, can save ~Rs150mn).

Our view: Rough calculation suggests ~20% upside to IPO price

The balance sheet is strong with net debt/EBITDA of 1x (FY19: 3.5x). Venus has the potential to generate EBITDA of Rs900mn-1bn/year (~2x from FY22 annualized EBITDA) at full capacity which can happen in FY25. The EBITDA increase should happen on volume expansion (capacity increasing from 10,800tpa to 24,000 tpa), improved customer mix by shifting sales from stockiest to direct sales/tender based, backward integration and improving operating efficiencies. It can generate net profits of ~Rs600mn (assuming EBITDA of ~Rs900mn). Assigning 14x (30% discount to Ratnamani Metal and Tubes’s FY24 consensus P/E), potential market cap could be ~Rs8.4bn, providing ~20% upside.

Venus existing capacity and expansion plans

Venus has manufacturing plant at Dhaneti, Kutch in Gujarat, having installed capacity of SS pipes and tubes of 10,800tpa. It manufactures welded as well as seamless SS pipes. Venus is amid increasing the overall SS pipes capacity to 24,000tpa and increase product offerings of different sizes and higher diameter. Welded pipes capacity is proposed to increase from

existing 7,200tpa to 14,400tpa and seamless pipes from 3,600tpa to 9,600tpa. It is expected to be completed by FY23 end at total capex of Rs1060mn.

Conclusion: Should You Invest or Not?

As the commodity prices are rising we will see higher growth and the profit margin will increase in the coming quarters and fiscal year. The company is on a plan of expansion, to double the capacity in FY23. The financial results are looking strong and the growing sector will give more boost in the coming years. As the issue size is below Rs.250 crores the listing will be in the “T” Group. There will be a circuit limit of 5% on the listing price on a listing day. As per the data we saw in the above thread we recommend applying IPO with medium to long term perspectives.

Note: All the information published in the article is added as per the research from online sources and brokerage firms. The information is for educational purposes only. We do not claim any facts, or figures mentioned here. If you have any query regarding this article please email us on ipowatchinfo (at) gmail (dot) com.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.